{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:57:05Z","timestamp":1781672225206,"version":"3.54.5"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypertension remains a major global risk factor for cardiovascular disease. While clinical trials suggest that lower systolic blood pressure (SBP) levels reduce cardiovascular risk, real-world data from high-risk patients remain limited. This study evaluated the association between achieved SBP levels and cardiovascular outcomes in a high-risk hypertensive population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective cohort study from January 2022 to December 2024, including 180 high-risk hypertensive patients receiving treatment at a tertiary care facility. Patients were categorized based on achieved systolic blood pressure during follow-up: one group with SBP &amp;lt;120\u2005mmHg and another with SBP between 130 and 139\u2005mmHg. The primary endpoint was a composite of major adverse cardiovascular events (MACE), including myocardial infarction, stroke, heart failure, and cardiovascular-related death or hospitalization. The secondary outcomes consisted of all-cause mortality and adverse treatment events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients in the lower achieved SBP group had significantly fewer MACE events over a median follow-up of 18 months compared with those in the higher SBP group (14.8 vs. 26.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). Treatment was considered to be particularly of benefit for patients with diabetes and chronic kidney disease because the relative risk reduction was 30% compared to routine control. There was attenuation of benefits in elderly patients, i.e., where age was over 75. Adverse events, including hypotension and renal impairment, were slightly more common in the lower SBP group but remained clinically manageable (9.3% vs. 4.8%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.60).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among high-risk hypertensive patients, lower achieved SBP levels were associated with reduced cardiovascular event rates. These findings support the need for further prospective studies to define optimal BP targets, especially in patients with diabetes and chronic kidney disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1711504","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:49:34Z","timestamp":1781671774000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective cohort study assessing cardiovascular risk reduction through intensive blood pressure management in high-risk patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Baihui","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Affiliated Chongming Hospital of Shanghai University of Medicine & Health Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Affiliated Chongming Hospital of Shanghai University of Medicine & Health Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"14594","DOI":"10.1038\/s41598-025-99358-1","article-title":"Global burden of hypertensive heart disease and attributable risk factors, 1990\u20132021: insights from the global burden of disease study 2021","volume":"15","author":"Wu","year":"2025","journal-title":"Sci Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e041964","DOI":"10.1161\/JAHA.125.041964","article-title":"Cardiovascular disease attributable to high systolic blood pressure in younger adults requires greater attention: insights from the global burden of disease study 2021","volume":"14","author":"Li","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"B3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12872-025-04807-4","article-title":"Trends in the global, regional, and national burden of cardiovascular diseases attributed to high systolic blood pressure from 1990 to 2021 and projections to 2045: a systematic analysis based on GBD 2021 data","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"B4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.36303\/SAPJ.2566","article-title":"Hypertension in South Africa: a growing epidemic and evolving treatment paradigms","volume":"6","author":"Jordaan","year":"2025","journal-title":"S Afr Gen Pract"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2545952","DOI":"10.1080\/17441692.2025.2545952","article-title":"Challenges and opportunities in screening and management of hypertension and type 2 diabetes in informal settlements in Nairobi, Kenya: a qualitative study of multi-sectoral stakeholders","volume":"20","author":"Nam","year":"2025","journal-title":"Glob Public Health"},{"key":"B6","first-page":"1175898","article-title":"Editorial: Aging and chronic disease: public health challenge and education reform","volume-title":"Front Public Health","author":"Sun","year":"2023"},{"key":"B7","article-title":"Hypertension in diabetes","author":"Naha","year":"2021","journal-title":"Endotext"},{"key":"B8","doi-asserted-by":"publisher","first-page":"E102","DOI":"10.1503\/jpn.240105","article-title":"Cardiometabolic risk factors and brain age: a meta-analysis to quantify brain structural differences related to diabetes, hypertension, and obesity","volume":"50","author":"Selitser","year":"2025","journal-title":"J Psychiatry Neurosci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4103\/jrms.jrms_470_23","article-title":"The connection between hypertension and diabetes and their role in heart and kidney disease development","volume":"29","author":"Hezam","year":"2024","journal-title":"J Res Med Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","article-title":"Residual cardiovascular risk: when should we treat it?","volume":"120","author":"Gomez-Delgado","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/00325481.2022.2052516","article-title":"The debate over the optimal blood pressure treatment target of less than 130\/80 mmHg","volume":"135","author":"Chrysant","year":"2023","journal-title":"Postgrad Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1161\/HYPERTENSIONAHA.121.17233","article-title":"Blood pressure intervention and control in SPRINT","volume":"79","author":"Cushman","year":"2022","journal-title":"Hypertension"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/HJH.0000000000004037","article-title":"Optimizing benefits of intensive SBP control in type 2 diabetes: the crucial role of angiotensin-converting enzyme inhibitors\/angiotensin-II type 2 receptor blockers","volume":"43","author":"Lin","year":"2025","journal-title":"J Hypertens"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e011872","DOI":"10.1161\/CIRCOUTCOMES.124.011872","article-title":"Cost-effectiveness of hypertension treatment according to 2017 American College of Cardiology and American Heart Association guidelines","volume":"18","author":"Penko","year":"2025","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e390456","DOI":"10.1200\/EDBK_390456","article-title":"Systemic therapy in older patients with high-risk disease","volume":"43","author":"Brain","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2021.01.014","article-title":"Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension","volume":"77","author":"Fatani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e000123","DOI":"10.1136\/bmjdrc-2015-000123","article-title":"Design of and rationale for the Japan diabetes optimal integrated treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial","volume":"4","author":"Ueki","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","article-title":"Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis","volume":"2","author":"Bundy","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"2507686","DOI":"10.1080\/08037051.2025.2507686","article-title":"Association between 24-hour blood pressure variability and mortality in acute ischemic stroke patients admitted in intensive care units: a MIMIC-IV study","volume":"34","author":"Yuan","year":"2025","journal-title":"Blood Press"},{"key":"B20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/5584_2016_97","article-title":"Treatment of hypertension: which goal for which patient","volume":"956","author":"Jarraya","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00134-017-4718-z","article-title":"The status of intensive care medicine research and a future agenda for very old patients in the ICU","volume":"43","author":"Flaatten","year":"2017","journal-title":"Intensive Care Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1711504\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:49:39Z","timestamp":1781671779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1711504\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":21,"alternative-id":["10.3389\/fcvm.2026.1711504"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1711504","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1711504"}}